Statin—Fibrate Combination Therapy

  title={Statin—Fibrate Combination Therapy},
  author={Allen Shek and Mary J. Ferrill},
  journal={Annals of Pharmacotherapy},
  pages={908 - 917}
BACKGROUND: Precautionary warnings for severe myopathy and rhabdomyolysis from the coadministration of statins and fibrates have been well publicized. However, a recent cerivastatin labeling change made the combined use with fibric acid derivatives a contraindication. Practical recommendations for clinicians who care for patients with refractory mixed hyperlipidemia are needed. OBJECTIVE: To provide recommendations for clinicians in the treatment of refractory mixed hyperlipidemia. DATA SOURCES… 

Tables from this paper

Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy
The identification of patients with an increased proclivity to statin-induced myopathy could allow more cost-effective approaches of monitoring and screening, facilitate targeted prevention of potential complications, and further improve the already overwhelmingly positive benefit-risk ratio of statins.
Simvastatin–Fluconazole Causing Rhabdomyolysis
Patients receiving statins who have cancer may receive azole antifungals and other drugs that inhibit CYP3A4 during treatment, predisposing them to toxicity, and patients should be monitored closely for drug interactions.
Safety considerations with fibrate therapy.
Statin-fibrat kombinasyon tedavisi
The role of combined statin-fibrate therapy in dyslipidemia, their mechanisms of action, efficacy and safety, and precautions needed to be taken to reduce side effects are reviewed in the light of literature.
Rhabdomyolysis and statin therapy: relevance to the elderly.
  • D. SicaT. Gehr
  • Medicine, Biology
    The American journal of geriatric cardiology
  • 2002
Physicians must take many factors into account when selecting a member of the HMG-CoA reductase inhibitor class, particularly as relates to their use in the multiply medicated elderly patient.
[Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? A case report].
It is considered that hypolipemic treatment probably revealed previously occult autoimmune thyroid disease in this patient, and the introduction of thyroid hormone supplementation led to regression of symptoms and normalization of abnormalities found in laboratory examinations including remarkable improvement in lipid profile.
Myotoxicity associated with lipid-lowering drugs
Management of myotoxicity requires an evaluation of risk factors prior to prescribing lipid-lowering drugs, attention to muscle symptoms, and withdrawal of drug in the event of significant abnormalities.
Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins
This is the largest phase III randomized, controlled clinical programme to date evaluating the efficacy and safety of the combined use of a new formulation of fenofibric acid with three commonly prescribed statins in patients with mixed dyslipidaemia.
Statin-associated myopathy.
A literature review found that reports of muscle problems during statin clinical trials are extremely rare and the risk of rhabdomyolysis and other adverse effects with statin use can be exacerbated by several factors, including compromised hepatic and renal function, hypothyroidism, diabetes, and concomitant medications.
Rhabdomyolysis in Association with Simvastatin and Amiodarone
Avoiding the concomitant use of drugs with the potential to inhibit CYP-dependent metabolism (eg, amiodarone) or elimination of statins may decrease the risk of statin-associated myopathy.


Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy.
A case of rhabdomyolysis and acute renal failure in a patient receiving gemfibrozil as the only lipidlowering agent, and in absence of any other drug or clinical condition recognized as cause of r rehabilitation, is reported.
Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.
A case of severe myopathy and rhabdomyolysis associated with concomitant use of simvastatin and gemfibrozil is described.
Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study.
A 57-year-old woman with hyperlipidemia, treated with lovastatin and gemfibrozil, was admitted to the hospital for evaluation of muscular weakness in her legs and neck who developed a rapidly progressive necrotizing myopathy.
Dual bezafibrate‐simvastatin therapy for combined hyperlipidaemia
It is concluded that dual simVastatin‐bezafibrate therapy is well tolerated and may reduce triglyceride concentrations, but offers no advantage in cholesterol reduction over treatment with simvastatin alone.